{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:25Z","timestamp":1791499285911,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer(OC) remains a major threat to women\u2019s health, ranking among the top gynecologic malignancies in both incidence and mortality. Current clinical management continues to center on cytoreductive surgery combined with a multidisciplinary approach incorporating chemotherapy, targeted therapy, and immunotherapy. Notably, while single-agent immunotherapy has demonstrated limited efficacy in recurrent OC, recent breakthrough advances in dual-target immunotherapy have brought new hope for advanced-stage and recurrent patients. Clinical evidence indicates that programmed death-1\/cytotoxic T-lymphocyte-associated protein 4 (PD-1\/CTLA-4) dual immune checkpoint blockade strategies (e.g., durvalumab plus tremelimumab, nivolumab plus ipilimumab) exhibit differential therapeutic effects: durable treatment responses have been observed in recurrent\/platinum-resistant advanced OC, while neoadjuvant applications have significantly improved complete resection rates. However, these therapeutic benefits demonstrate marked heterogeneity across different histological subtypes. The review of current research reveals several critical issues: first, the safety profile of dual immunotherapy requires further characterization; second, data on first-line treatment for advanced OC remain scarce; and third, optimal treatment strategies have yet to be established. Nevertheless, multiple ongoing clinical trials are paving the way for future research directions, including optimization of combination regimens and exploration of predictive biomarkers. In conclusion, despite existing challenges, dual-target immunotherapy has demonstrated clinically meaningful benefits, offering new therapeutic options for advanced and recurrent OC patients and heralding a new era of combination immunotherapy in OC treatment. Future large-scale clinical studies are warranted to further validate efficacy and establish individualized precision treatment strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1686532","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:24:39Z","timestamp":1762151079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Dong-Mei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ge","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Zhang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug      resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: A narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + Chemotherapy versus placebo + Chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of keynote-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102254","article-title":"A first-in-human phase I study of the pd-1 inhibitor, retifanlimab (Incmga00012), in patients with advanced solid tumors (Pod1um-101)","volume":"9","author":"Lakhani","year":"2024","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of pd-L1 in patients with gynecological cancers: an updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/ijms20122927","article-title":"Ovarian cancer immunotherapy: turning up the heat","volume":"20","author":"Ghisoni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459","article-title":"Cd28 and ctla-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459","article-title":"Cd28 and ctla-4 have opposing effects on the response of T-cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-ctla-4 and anti-pd-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative ctla-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806075105","article-title":"Ctla-4 blockade increases ifngamma-producing cd4+Icoshi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/JCO.2020.38.15_suppl.6005","article-title":"Final results from the keynote-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer","volume":"38","author":"Matulonis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (Javelin ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00437-6","article-title":"Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (Inova): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Peng","year":"2024","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.3390\/cancers15123220","article-title":"Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10859","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Pawlowska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.20.01986","article-title":"Randomized phase ii trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an nrg oncology study (Vol 56, pg 770, 2020)","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase ii trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an nrg oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0606","article-title":"Swog\/nci phase ii dual anti-ctla-4\/pd-1 blockade in rare tumors: nonepithelial ovarian cancer","volume":"30","author":"Chae","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of bruog 354: A randomized phase ii trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e45","article-title":"Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (Ambition; kgog 3045): A multicentre, open-label, five-arm, uncontrolled, umbrella trial","volume":"33","author":"Lee","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007444","article-title":"Phase ii study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of kgog3046\/tru-D","volume":"11","author":"Park","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3753","article-title":"Neoadjuvant chemotherapy with dual immune checkpoint inhibitors for advanced-stage ovarian cancer: final analysis of tru-D phase ii nonrandomized clinical trial","volume":"31","author":"Park","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/jco.2024.42.16_suppl.5569","article-title":"Phase ib ineov neoadjuvant trial of durvalumab plus\/- tremelimumab with platinum chemotherapy for patients (Pts) with unresectab le ovarian cancer (Oc): survival outcomes and immune correlates","volume":"42","author":"Leary","year":"2024","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(21)00718-6","article-title":"Randomized phase ii trial of durvalumab (Anti-pdl1) and tremelimumab (Anti-ctla4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (Nct03026062)","volume":"162","author":"Hinchcliff","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e17552","article-title":"An open, prospective, single arm, phase ii study of cadonilimab (Pd-1\/ctla-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: interim analysis from the ak104-iit-003 study","volume":"42","author":"Tang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.514","article-title":"Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (Anti-pd-1) in patients with recurrent platinum refractory\/resistant ovarian cancer","volume":"176","author":"Bockorny","year":"2023","journal-title":"Gynecologic Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-IGCS.480","article-title":"First-in-human phase 1\/2 study of ubamatamab, a muc16xcd3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer","volume":"33","author":"Moore","year":"2023","journal-title":"Int J Gynecological Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.422","article-title":"A phase I\/ii study of ubamatamab (Regn4018), a muc16xcd3 bispecific antibody, administered alone or in combination with cemiplimab (Anti-pd-1) in patients with recurrent ovarian cancer or muc16+Endometrial cancer: trial in progress update","volume":"190","author":"Liu","year":"2024","journal-title":"Gynecologic Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00962-3","article-title":"Cadonilimab is effective and safe in recurrent cervical cancer","volume":"22","author":"Romero","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101785","article-title":"Patient with hr-proficient advanced ovarian cancer achieved a complete response with cadonilimab combined chemotherapy (Pd-1\/ctla-4 bispecific): A case report and literature review","volume":"60","author":"Zhang","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1200\/JCO.2023.41.16_suppl.5040","article-title":"A single-arm, phase ii study of durvalumab (D) and tremelimumab (T) for relapsed\/refractory germ cell tumors (Gct)","volume":"41","author":"Funt","year":"2023","journal-title":"J Clin Oncol"},{"key":"B45","unstructured":"Randomized active-controlled trial evaluating ql1706 plus bevacizumab versus platinum-based chemotherapy for advanced first-line ovarian clear cell carcinoma\n          \n          2025"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.023","article-title":"Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer","volume":"151","author":"Kim","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/cancers12071761","article-title":"Preclinical and clinical immunotherapeutic strategies in epithelial ovarian cancer","volume":"12","author":"Martinez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2370","article-title":"Mek inhibition remodels the immune landscape of mutant kras tumors to overcome resistance to parp and immune checkpoint inhibitors","volume":"81","author":"Yang","year":"2021","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","article-title":"Durvalumab with paclitaxel\/carboplatin (Pc) and bevacizumab (Bev), followed by maintenance durvalumab, bev, and olaparib in patients (Pts) with newly diagnosed advanced ovarian cancer (Aoc) without a tumor brca1\/2 mutation (Non-tbrcam): results from the randomized, placebo (Pbo)-controlled phase iii duo-O trial","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.271","article-title":"Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types","volume":"8","author":"Budczies","year":"2022","journal-title":"J Pathol Clin Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399926","article-title":"Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cgas-sting pathway strategies","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in parp inhibitor-naive platinum-sensitive relapsed ovarian cancer: A phase ii multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-024-09913-z","article-title":"Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism","volume":"27","author":"Yang","year":"2024","journal-title":"Angiogenesis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003231","article-title":"Tumor angiogenesis and anti-angiogenic therapy","volume":"137","author":"Guo","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage iii or iv ovarian cancer: placebo-controlled randomized phase iii trial (Imagyn050\/gog 3015\/engot-ov39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.595436","article-title":"Association of cldn6 and cldn10 with immune microenvironment in ovarian cancer: A study of the claudin family","volume":"12","author":"Gao","year":"2021","journal-title":"Front Genet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2032","article-title":"Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the imagyn050 randomized clinical trial","volume":"29","author":"Landen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/jpm12071176","article-title":"Comprehensive genomic profiling in the management of ovarian cancer-national results from Croatia","volume":"12","author":"Cerina","year":"2022","journal-title":"J Pers Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.03.013","article-title":"An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for tgfbeta blockade therapy","volume":"12","author":"Pomponio","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489235","article-title":"Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy","volume":"15","author":"Gronauer","year":"2024","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101901","article-title":"Insights into molecular mechanisms of chemotherapy resistance in cancer","volume":"42","author":"Kar","year":"2024","journal-title":"Transl Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:24:41Z","timestamp":1762151081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1686532"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1686532","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1686532"}}